Written by Jane Aubrey
The U.S. Food and Drug Administration has approved Zanvastro, or zilganersen, for pediatric and adult patients with Alexander disease. The September 3 announcement makes Zanvastro the first FDA-approved treatment for this rare, progressive neurological disorder and the first therapy the agency says directly targets the protein buildup driving the disease. The approval is a meaningful milestone for a community that previously had supportive care but no approved disease-targeted therapy. It is also a case study in how regulators assemble evidence across a very small and clinically heterogeneous population.
Alexander disease is associated with mutations in the gene producing glial fibrillary acidic protein, or GFAP. The FDA explains that abnormal GFAP can accumulate in supportive brain cells and damage the nervous system over time. The disease affects fewer than one in a million people and may involve seizures, loss of developmental milestones, walking difficulty, weakness and increased pressure in the brain. Zanvastro is an antisense oligonucleotide designed to reduce production of the abnormal protein before it accumulates further. It is administered by injection into the spinal canal every three months by a trained healthcare professional.
The central evidence came from a multicenter, randomized, controlled study, NCT04849741, that enrolled 49 patients aged two years and older. In patients at least five years old who had measurable walking difficulty at baseline, the FDA says those receiving Zanvastro had significantly better walking speed at 61 weeks than patients receiving no treatment. In children aged two to four, for whom walking speed was not a reliable progression measure, the agency evaluated a broader motor-skill assessment covering standing, walking, running and jumping. Treated children improved on that measure while the control group declined.
That evidence is important because it is direct and controlled, but it is not identical across all ages. For patients younger than two, the FDA says direct trial data were limited by the rarity of the disease and the absence of a concurrent control group. The agency relied on pharmacokinetic modeling indicating that drug levels should be similar to those in older children at the same dose, supported by safety observations in four treated patients under two and the safety profile observed in older pediatric patients. This is a rational rare-disease evidence bridge, but it should not be mistaken for the same quantity of direct clinical efficacy data available in the randomized age groups.
The label spans infancy through adulthood because the FDA evaluated the available evidence across the disease spectrum. That breadth has practical significance for families and clinicians, yet individual expectations should remain tethered to the patient’s age, baseline function, disease course and the evidence applicable to that subgroup. Approval establishes that the agency concluded the benefits outweigh risks for the indicated population. It does not guarantee a uniform response, reverse existing neurological injury or remove the need for supportive multidisciplinary care.
Safety and administration deserve equal attention. The FDA lists vomiting, back pain, cough, headache and post-lumbar-puncture syndrome among the most common side effects. It also notes that aseptic meningitis has been reported and advises patients and caregivers to discuss symptoms consistent with meningitis with their healthcare provider. Intrathecal delivery every three months requires trained professionals and creates a procedural dimension that is different from an oral therapy. Access, site capability, monitoring and travel can therefore shape real-world use even after approval.
Zanvastro received Orphan Drug, Fast Track, Breakthrough Therapy, Rare Pediatric Disease and Priority Review Voucher designations. These designations reflect the seriousness and rarity of the condition and can facilitate development and review; they are not substitutes for the clinical evidence that supported approval. The next phase is pharmacovigilance and clinical implementation: gathering broader safety experience, understanding durability and documenting outcomes across age groups and disease presentations. For a disorder this rare, every carefully collected real-world observation can improve clinical understanding, but it should complement—not replace—the controlled evidence behind the decision.
This article is informational and educational only, not medical advice. Treatment decisions, including whether Zanvastro is appropriate for an individual, should be made with qualified clinicians using the full FDA prescribing information and current clinical guidance.
